unknown
Stage
About
APIM Therapeutics AS is a Norwegian biotech developing peptide drugs that target PCNA-dependent stress responses in cancer cells; its lead clinical-stage candidate ATX-101 has been tested in phase Ib ovarian cancer and phase II sarcoma studies.
Explore APIM Therapeutics AS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.